RISK BASED INSPECTION [SCHEDULE M & WHO TRS 986-POINT (32.1-32.4)]
![RISK BASED INSPECTION [SCHEDULE M & WHO TRS 986-POINT (32.1-32.4)]](https://pharmadevils.com/wp-content/uploads/2024/10/SCHEDULE-M-WHO-TRS-986-32.1-32.4-768x1087.jpg)
In a risk-based inspection (RBI), Schedule M & WHO TRS 986 (Points 32.1–32.4) are evaluated under Master Formula Records (MFRs) because weak master documentation is a top driver of wrong process execution, wrong quantities, mix-ups, and repeat deviations. 32.1 –…





![RISK BASED INSPECTION [SCHEDULE M & WHO TRS 986-POINT (31.1-31.4)]](https://pharmadevils.com/wp-content/uploads/2024/10/SCHEDULE-M-WHO-TRS-986-31.1-31.4-768x1087.jpg)
![RISK BASED INSPECTION [SCHEDULE M -POINT (15.6-15.8)]](https://pharmadevils.com/wp-content/uploads/2024/10/SCHEDULE-M-15.6-15.8-768x1087.jpg)
![RISK BASED INSPECTION [SCHEDULE M -POINT (15.1-15.5)]](https://pharmadevils.com/wp-content/uploads/2024/10/SCHEDULE-M-15.1-15.5-768x1087.jpg)
![RISK BASED INSPECTION [SCHEDULE M & WHO TRS 986-POINT (14.16-14.20)]](https://pharmadevils.com/wp-content/uploads/2024/10/SCHEDULE-M-WHO-TRS-986-14.16-14.20-768x1087.jpg)
![RISK BASED INSPECTION [SCHEDULE M-POINT (14.10-14.15)]](https://pharmadevils.com/wp-content/uploads/2024/10/SCHEDULE-M-14.10-14.15-768x1086.jpg)
![RISK BASED INSPECTION [SCHEDULE M-POINT (14.6-14.9)]](https://pharmadevils.com/wp-content/uploads/2024/10/SCHEDULE-M-14.6-14.9-768x1087.jpg)
![RISK BASED INSPECTION [SCHEDULE M-POINT (14.3-14.5)]](https://pharmadevils.com/wp-content/uploads/2024/10/SCHEDULE-M-14.3-768x1086.jpg)
![RISK BASED INSPECTION [SCHEDULE M-POINT (14.2)]](https://pharmadevils.com/wp-content/uploads/2024/10/SCHEDULE-M-14.2-768x1087.jpg)
![RISK BASED INSPECTION [SCHEDULE M-POINT (14.1)]](https://pharmadevils.com/wp-content/uploads/2024/10/SCHEDULE-M-14.1-768x1087.jpg)